These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19601997)

  • 1. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.
    Taiwo BO; Li X; Palella F; Jacobson LP; Margolick JB; Detels R; Rinaldo CR; Phair JP
    HIV Med; 2009 Nov; 10(10):657-60. PubMed ID: 19601997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy.
    Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX
    Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive role of CD4
    Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ
    BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.
    Marconi VC; Grandits G; Okulicz JF; Wortmann G; Ganesan A; Crum-Cianflone N; Polis M; Landrum M; Dolan MJ; Ahuja SK; Agan B; Kulkarni H;
    PLoS One; 2011; 6(5):e17956. PubMed ID: 21625477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical outcome and immune reconstitution in 45 advanced AIDS patients undergoing highly active antiretroviral therapy for 12 months].
    Ruan GR; Qiu ZF; Li TS; Han Y; Xie J; Zuo LY; Ma XJ; Liu ZY; Wang AX
    Zhonghua Nei Ke Za Zhi; 2006 Jul; 45(7):569-72. PubMed ID: 17074113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
    HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
    Chêne G; Sterne JA; May M; Costagliola D; Ledergerber B; Phillips AN; Dabis F; Lundgren J; D'Arminio Monforte A; de Wolf F; Hogg R; Reiss P; Justice A; Leport C; Staszewski S; Gill J; Fatkenheuer G; Egger ME;
    Lancet; 2003 Aug; 362(9385):679-86. PubMed ID: 12957089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
    ; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
    PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.
    Minidis NM; Mesner O; Agan BK; Okulicz JF
    J Int AIDS Soc; 2014; 17(1):18799. PubMed ID: 24499779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.
    Anastos K; Barrón Y; Miotti P; Weiser B; Young M; Hessol N; Greenblatt RM; Cohen M; Augenbraun M; Levine A; Muñoz A;
    Arch Intern Med; 2002 Sep; 162(17):1973-80. PubMed ID: 12230420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.